ADSB-FUB-187.

ADSB-FUB-187 belongs to the indazole-3-carboxamides, the family that includes the FUBINACA and PINACA series, here with an indazole core chlorinated at position 7 and a tert-leucine chain extended by a cyclopropane sulfonamide. What is established amounts to few lines: the compound comes from a 2009 pharmaceutical patent devoted to CB1 modulators (the patent mentions pain), and the only published values, taken up in 2018 by the review of Banister and Connor (full text not re-read), give an affinity of about 0.09 nM and a potency of about 1.09 nM at the human CB1 receptor, measured by membrane binding and by GTPγS binding. No independent study has revisited this pharmacology: the maximal efficacy of the molecule has not been determined, its activity at CB2 has not been measured, no work on metabolism, pharmacokinetics or toxicology concerns it, and human data are entirely lacking. No published clinical case is attributed to it, which does not mean that it is harmless: for the class of synthetic agonists, the ACMD describes confusion, anxiety, agitation, psychosis, vomiting, seizures, cardiac rhythm disturbances and liver or kidney failure, sometimes fatal; these observations concern the class, not this molecule. No therapeutic benefit is established.

Source

An entirely synthetic molecule, absent from cannabis and from every living organism, with no connection to hemp or to cannabidiol products. Created in a pharmaceutical laboratory, it subsequently circulated as a so-called research chemical, then as a psychoactive substance: its listing in the inventory of the United Nations Office on Drugs and Crime and its scheduling by name in France both attest that it has left the laboratory setting behind.

No biosynthetic pathway exists: the molecule comes from no living organism and derives from no plant precursor. It belongs exclusively to synthetic chemistry.

European Union

There is no single list of narcotics at European Union level: control falls to national laws and to the United Nations conventions. ADSB-FUB-187 appears in no schedule of the 1961 and 1971 Conventions, and it has been the subject of neither a joint report nor a risk assessment by the European drugs agency, unlike several synthetic agonists placed under control throughout the Union after such a procedure. It is, however, listed in the inventory of new psychoactive substances of the United Nations Office on Drugs and Crime, under synthetic cannabinoid receptor agonists. France has named it since 2017.

France

ADSB-FUB-187 is scheduled as a narcotic in France by name. The substance was added to annex IV of the decree of 22 February 1990 setting the list of substances classified as narcotics, in the section devoted to cannabinoids, by the decree of 31 March 2017 published in the Journal officiel of 6 April 2017; it still appears in the consolidated list maintained by the ANSM. It is therefore not an indirect attachment through the generic clause covering tetrahydrocannabinols, their esters, their ethers and their salts (in annex III since the decision of 6 February 2026): that clause does not cover the structure, which is neither an ester, nor an ether, nor a salt of THC. The listing extends to the isomers, stereoisomers, esters, ethers and salts of the substance. Production, possession, transfer, importation and use fall under the criminal regime applying to narcotics. The molecule has no food, cosmetic or therapeutic status and enters into no legal CBD product.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indazole-3-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

ADSB-FUB-187 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1Banister SD, Connor M. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. Handb Exp Pharmacol. 2018;252:191-226 (source of the CB1 values attributed to the patent for ADSB-FUB-187; full text not re-read) (new tab)PMID 30105473
2. 2Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK. Indazole derivatives (CB1 receptor agonists). Patent WO 2009/106982, Pfizer Inc., priority of 29 February 2008, published 3 September 2009 (the text names 7-chloro-N-{(1S)-1-[({2-[(cyclopropylsulfonyl)amino]ethyl}amino)carbonyl]-2,2-dimethylpropyl}-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; per-compound values not found in the text) (new tab)
3. 3United Nations Office on Drugs and Crime (UNODC), Early Warning Advisory on New Psychoactive Substances, ADSB-FUB-187 record (group: synthetic cannabinoids; effect: cannabinoid receptor agonists) (new tab)
4. 4Order of 31 March 2017 amending the order of 22 February 1990 setting the list of substances classified as narcotics (Annex IV, ADSB-FUB-187 named), JORF of 6 April 2017, Légifrance (new tab)
5. 5ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (Annex IV, entry ADSB-FUB-187 in the cannabinoid list) (new tab)
6. 6PubChem, Compound Summary CID 44186812, ADSB-FUB-187 (formula, InChIKey, synonyms) (new tab)
7. 7ACMD, Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists, Home Office, 2023: effects described for the class of synthetic agonists (new tab)

SMILES

CC(C)(C)[C@@H](C(=O)NCCNS(=O)(=O)C1CC1)NC(=O)C2=NN(C3=C2C=CC=C3Cl)CC4=CC=C(C=C4)F

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.